Filing Details
- Accession Number:
- 0001179110-15-015176
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-11-19 18:03:17
- Reporting Period:
- 2015-11-17
- Filing Date:
- 2015-11-19
- Accepted Time:
- 2015-11-19 18:03:17
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1157601 | Synta Pharmaceuticals Corp | SNTA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1325712 | R Keith Gollust | C/O Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington MA 02421 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2015-11-17 | 100,000 | $0.41 | 2,885,061 | No | 4 | S | Indirect | By Wyandanch Partners, L.P. |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | By Wyandanch Partners, L.P. |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 401,764 | Direct | |
Common Stock | 175,000 | Indirect | By Keith R. Gollust IRA |
Footnotes
- This transaction was executed in multiple trades at prices ranging from $0.4005 to $0.4306 per share. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.